SNPMiner Trials (Home Page)
Report for Mutation A27L
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
This phase I/II study is directed at evaluating safety and immunogenicity of a melanoma
peptide vaccine in combination or not with Dacarbazine administration in melanoma patients
NCT00559026 Melanoma Biological: Melan-A Other: Melan-A plus Dacarbazine
injections of Melan-A: 26-35 (A27L) and gp100:
209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. --- A27L ---
Primary Outcomes Measure: Assessment of safety by evaluating local and systemic adverse reactions during the trial. Assessment of the vaccine-specific cellular immune responses Time: one year
Secondary Outcomes Measure: Assessment of relapse-free survival and overall survival calculated from the time of the first chemotherapy/vaccine injection. Evaluation by microarray analysis of the gene expression profiles of patients PBMC 24 h after DTIC administration. Time: two years